Table 3.

Summary of cases who took an extended course of Paxlovid within the context of an acute re-infection

Case #	Age, gender	Date of COVID infection(s)	Likely variant	Initiation of Long COVID symptoms	COVID vaccinations	Date and length of extended course of Paxlovid	Short-term improvement with Paxlovid	Sustained improvement with Paxlovid	Adverse effects of Paxlovid
12	41 y.o. woman	Dec 2020	alpha	Dec 2020	2021 (Mar, Apr), 2022 (Jan, Nov)	Apr 2023 (10 d during acute infection)	(returned to pre-reinfection baseline within 2 months)		y
13	55 y.o. transgender person	Mar 2020, Mar 2021, Dec 2022	original wild type, alpha, omicron	Mar 2020	2021 (Feb, July, Oct), 2022 (Oct), 2023 (Apr)	Dec 2022 (7.5 d during acute infection)	(returned to pre-reinfection baseline within 3 weeks)